Amgen Inc. - Product Pipeline Review - 2016

Date: March 30, 2016
Pages: 251
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AD9AF912D01EN
Leaflet:

Download PDF Leaflet

Amgen Inc. - Product Pipeline Review - 2016

SUMMARY

Global Markets Direct’s, ‘Amgen Inc. - Product Pipeline Review - 2016’, provides an overview of the Amgen Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Amgen Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the pipeline therapeutic landscape of Amgen Inc.
  • The report provides overview of Amgen Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Amgen Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Amgen Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
REASONS TO BUY
  • Evaluate Amgen Inc.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Amgen Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Amgen Inc.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Amgen Inc. Snapshot
Amgen Inc. Overview
Key Information
Key Facts
Amgen Inc. - Research and Development Overview
Key Therapeutic Areas
Amgen Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Amgen Inc. - Pipeline Products Glance
Amgen Inc. - Late Stage Pipeline Products
Amgen Inc. - Clinical Stage Pipeline Products
Amgen Inc. - Early Stage Pipeline Products
Amgen Inc. - Drug Profiles
adalimumab biosimilar
blinatumomab
darbepoetin alfa
denosumab
etanercept
etelcalcetide hydrochloride
romiplostim
AMG-334
bevacizumab biosimilar
evolocumab
fulranumab
panitumumab
rituximab biosimilar
romosozumab
trastuzumab biosimilar
trebananib
abrilumab
AMG-319
AMG-337
AMG-557
AMG-714
AMG-899
ganitumab
omecamtiv mecarbil MR
rilotumumab
tezepelumab
AMG-232
talimogene laherparepvec
AMG-172
AMG-208
AMG-211
AMG-224
AMG-228
AMG-282
AMG-301
AMG-330
AMG-357
AMG-581
AMG-592
AMG-595
AMG-780
AMG-811
AMG-820
AMG-876
AMG-900
AMG-XXX
infliximab biosimilar
pasotuxizumab
solitomab
AM-1638
AM-3189
AM-6226
AM-7209
AM-8553
AM-9514
AMG-0696
AMG-161
AMG-1694
AMG-176
AMG-3969
AMG-511
AMG-570
AMG-8718
AMG-986
Biosimilar 1 for Undisclosed Indication
Biosimilar 2 for Undisclosed Indication
Biosimilar 3 for Undisclosed Indication
Calcimimetic-18
cetuximab biosimilar
Drug for Atherosclerosis
Drugs to Inhibit FGF23 for Bone Disorders
Morpholinone-27
Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases
Recombinant Protein to Agonize FGFR for Type 2 Diabetes
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes
Small Molecule to Agonize GPR119 for Undisclosed Indication
Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication
Small Molecule to Agonize GPR142 for Type 2 Diabetes
Small Molecule to Antagonize EP2 Receptor for Alzheimer Disease
Small Molecule to Inhibit BACE1 for Alzheimer's Disease
Small Molecule to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis
Small Molecule to Inhibit PI3K/mTOR for Cancer
Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
Small Molecules to Inhibit BACE1 for Alzheimer Disease
Small Molecules to Inhibit PDE10A for Neurological Diseases
Small Molecules to Inhibit PI3K Delta for Inflammation
XmAb-13243
XmAb-13551
AA-71
Drugs for Inflammatory Bowel Disease
Monoclonal Antibodies for Cancer and Inflammation
Morpholinone-10
Morpholinone-16
Small Molecules to Inhibit CDC7 kinase for Cancer
Small Molecules to Inhibit IRAK-4 for Inflammation
Small Molecules to Inhibit NIK for Multiple Myeloma
Small Molecules to Inhibit Tankyrase for Cancer
Amgen Inc. - Pipeline Analysis
Amgen Inc. - Pipeline Products by Target
Amgen Inc. - Pipeline Products by Route of Administration
Amgen Inc. - Pipeline Products by Molecule Type
Amgen Inc. - Pipeline Products by Mechanism of Action
Amgen Inc. - Recent Pipeline Updates
Amgen Inc. - Dormant Projects
Amgen Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Amgen Inc. - Company Statement
Amgen Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Amgen Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Amgen Inc., Key Information
Amgen Inc., Key Facts
Amgen Inc. - Pipeline by Indication, 2016
Amgen Inc. - Pipeline by Stage of Development, 2016
Amgen Inc. - Monotherapy Products in Pipeline, 2016
Amgen Inc. - Partnered Products in Pipeline, 2016
Amgen Inc. - Partnered Products/ Combination Treatment Modalities, 2016
Amgen Inc. - Out-Licensed Products in Pipeline, 2016
Amgen Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Amgen Inc. - Pre-Registration, 2016
Amgen Inc. - Filing rejected/Withdrawn, 2016
Amgen Inc. - Phase III, 2016
Amgen Inc. - Phase II, 2016
Amgen Inc. - Phase I, 2016
Amgen Inc. - Preclinical, 2016
Amgen Inc. - Discovery, 2016
Amgen Inc. - Pipeline by Target, 2016
Amgen Inc. - Pipeline by Route of Administration, 2016
Amgen Inc. - Pipeline by Molecule Type, 2016
Amgen Inc. - Pipeline Products by Mechanism of Action, 2016
Amgen Inc. - Recent Pipeline Updates, 2016
Amgen Inc. - Dormant Developmental Projects,2016
Amgen Inc. - Discontinued Pipeline Products, 2016
Amgen Inc., Other Locations
Amgen Inc., Subsidiaries
Amgen Inc., Key Manufacturing Facilities

LIST OF FIGURES

Amgen Inc. - Pipeline by Top 10 Indication, 2016
Amgen Inc. - Pipeline by Stage of Development, 2016
Amgen Inc. - Monotherapy Products in Pipeline, 2016
Amgen Inc. - Partnered Products in Pipeline, 2016
Amgen Inc. - Out-Licensed Products in Pipeline, 2016
Amgen Inc. - Pipeline by Top 10 Target, 2016
Amgen Inc. - Pipeline by Route of Administration, 2016
Amgen Inc. - Pipeline by Molecule Type, 2016
Amgen Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


Ask Your Question

Amgen Inc. - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: